Phase II trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer (Oscillate)

被引：0
|
作者：
Mersiades, Antony [1 ]
Pavlakis, Nick [2 ]
Kao, Steven [3 ]
John, Tom [4 ]
Lee, Chee Khoon [1 ,5 ]
Dawson, Sarah-Jane [6 ]
Wong, Stephen [6 ]
Tan, Lavinia [6 ]
Yip, Sonia [1 ]
Brown, Chris [1 ]
Livingstone, Ann [1 ]
Cheung, Yvonne [1 ]
Jurkovic, Hannora [1 ]
Stockler, Martin [1 ]
机构：
[1] Univ Sydney, NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
[2] Royal North Shore Hosp, Dept Med Oncol, Sydney, NSW, Australia
[3] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[4] Olivia Newton John Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[5] St George Hosp, Dept Med Oncol, Sydney, NSW, Australia
[6] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
421
引用
收藏
页码：199 / 200
页数：2
相关论文
共 50 条
  • [1] A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE
    Tan, Lavinia
    Brown, Chris
    Mersiades, Antony
    Lee, Chee Khoon
    John, Thomas
    Kao, Steven
    Newnham, Genni
    O'Byrne, Kenneth
    Parakh, Sagun
    Bray, Victoria
    Jasas, Kevin
    Yip, Sonia
    Wong, Stephen Q.
    Ftouni, Sarah
    Guinto, Jerick
    Chandrashekar, Sushma
    Clarke, Stephen
    Pavlakis, Nick
    Stockler, Martin R.
    Dawson, Sarah-Jane
    Solomon, Benjamin J.
    [J]. NATURE COMMUNICATIONS, 2024, 15 (01)
  • [2] OSCILLATE - Phase 2 Trial of Alternating Osimertinib with Gefitinib in Patients with EGFR-T790M Mutation Positive Advanced NSCLC
    Solomon, B.
    Kok, P.
    Livingstone, A.
    Yip, S.
    Brown, C.
    Dawson, S.
    Wong, S.
    Pavlakis, N.
    Stockler, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2143 - S2143
  • [3] Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
    Yamada, T.
    Yoshimura, A.
    Takeda, T.
    Shiotsu, S.
    Hiranuma, O.
    Chihara, Y.
    Uchino, J.
    Takayama, K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1033 - S1033
  • [4] Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
    Yoshimura, Akihiro
    Yamada, Tadaaki
    Okura, Naoko
    Takeda, Takayuki
    Hirose, Kazuki
    Kubota, Yutaka
    Shiotsu, Shinsuke
    Hiranuma, Osamu
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Uchino, Junji
    Takayama, Koichi
    [J]. CANCERS, 2019, 11 (03)
  • [5] Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer
    Bertranou, Evelina
    Bodnar, Carolyn
    Dansk, Viktor
    Greystoke, Alastair
    Large, Samuel
    Dyer, Matthew
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 113 - 121
  • [6] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
    Kazuhisa Nakashima
    Yuichi Ozawa
    Haruko Daga
    Hisao Imai
    Motohiro Tamiya
    Takaaki Tokito
    Takahisa Kawamura
    Hiroaki Akamatsu
    Yuko Tsuboguchi
    Toshiaki Takahashi
    Nobuyuki Yamamoto
    Keita Mori
    Haruyasu Murakami
    [J]. Investigational New Drugs, 2020, 38 : 1854 - 1861
  • [7] Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial
    Nakashima, Kazuhisa
    Ozawa, Yuichi
    Daga, Haruko
    Imai, Hisao
    Tamiya, Motohiro
    Tokito, Takaaki
    Kawamura, Takahisa
    Akamatsu, Hiroaki
    Tsuboguchi, Yuko
    Takahashi, Toshiaki
    Yamamoto, Nobuyuki
    Mori, Keita
    Murakami, Haruyasu
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1854 - 1861
  • [8] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [9] EGFR-T790M Mutation-Derived Interactome Rerouted EGFR Translocation Contributing to Gefitinib Resistance in Non-Small Cell Lung Cancer
    Wu, Pei-Shan
    Lin, Miao-Hsia
    Hsiao, Jye-Chian
    Lin, Pei-Yi
    Pan, Szu-Hua
    Chen, Yu-Ju
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2023, 22 (09)
  • [10] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
12345